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ABSTRACT
Purpose Fosamprenavir, combined with low-dose ritonavir (FPV/r), is indicated for treatment of HIV-infected children aged ≥6 years in
Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV-infected children reported to six cohorts in the European
Pregnancy and Paediatric HIV Cohort Collaboration.
Methods Retrospective analysis of individual patient data for all children aged 6–18 years taking the licensed dose of FPV up to 31/12/10.
Adverse events (clinical events and absolute neutrophil counts, total cholesterol and triglycerides, and alanine transaminase) were
summarised and DAIDS gradings characterised severity.
Results Ninety-two HIV-infected children aged 6–18 years took the licensed dose, comprising 3% of the total number of children in
follow-up in participating cohorts. Median age at antiretroviral therapy initiation was 6 years (interquartile range 1–11 years), and median
age at start of FPV/r was 15 years (12–17 years). Estimated median time on an FPV-containing regimen was 52months, with a total of
266.9 patient years of exposure overall. Half (54%) were on an FPV-containing regimen at last follow-up. Rates of grade 3/4 events were
generally low for all biochemical toxicity markers, and no serious adverse events considered to be causally related to FPV/r were reported.
Conclusions Results suggest that long-term licensed dose FPV-containing regimens appear to be generally well tolerated with few
reported toxicities in HIV-infected children in Europe, although relatively infrequently prescribed. No serious events were reported.
© 2013 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
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INTRODUCTION
Fosamprenavir (FPV, Telzir™), combinedwith low-dose
ritonavir (FPV/r), was approved in Europe for treatment
of HIV-infected children aged ≥6 years in 2007.
Dosing is by weight: 18/3mg/kg twice daily (BID)
up to a maximum of 700/100mg for liquid formula-
tions; for children ≥39kg, 700/100mg BID for tablets.
Safety data from three FPV clinical trials in children
(APV20003, APV29005, and APV20002) have been
reported.1–3 Findings indicate that infections/infestation
and gastrointestinal events were the most commonly
reported adverse events (AEs). Treatment-emergent
grade 3/4 neutropenia was reported in less than 20%
of children across the studies but were considered
unlikely to be related to FPV.4 However, only one study
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to date has assessed FPV/r in routine clinical practice.
Palladino et al. studied 20 HIV-infected children over
a median of 180weeks and reported sustained antiviral
response and immunological improvement.5
We conducted a pharmacoepidemiology study to
assess the use and long-term safety of FPV in children
in ‘real world’ clinical settings in Europe. Individual
patient data originated from cohorts participating in
the European Pregnancy and Paediatric HIV Cohort
Collaboration (EPPICC), a network of European cohorts
of prospectively observed mother–child pairs and
children within EuroCoord (www.eurocoord.net).6
METHODS
Six cohorts participated in this study and reported data
for children aged 6–18 years who had ever taken FPV/
r to the end of 2010. Ethical approval was granted for
the study.
Children were considered to be on the licensed dose
if aged 6–18 years when taking FPV within a window
of +/20% of the licensed dose of 18mg/kg BID, or
on the adult dose (700mg BID, weight >39 kg), taken
with ritonavir, and outside of pharmaceutical company
trials.
The data speciﬁcation followed the HIV Cohorts
Data Exchange Protocol (HICDEP) (www.hicdep.
org). Data collected included demographics, deaths,
loss to follow-up, antiretroviral therapy (ART) treat-
ment history, AIDS events, biochemistry and AEs,
from the start of FPV/r use onwards. In addition, sum-
mary characteristics of all children (not just those on
FPV/r) in follow-up in each cohort were provided, to
estimate the extent of FPV/r use. Further, Intercontinen-
tal Medical Statistics (IMS) data on sales volumes of
FPV oral suspension were used as a surrogate measure
of paediatric exposure. We assumed that most children
aged 6–12 years would take fosamprenavir oral suspen-
sion rather than tablets because of their body weight
(tablets are not suitable for children <39kg).
Division of AIDS (DAIDS) gradings for paediatric
AEs were used to categorise severity of AEs,7 and
rates of grade ≥3 events by time since FPV initiation
(<12, 12–24, and >24months) were estimated (per
100 person years). Analyses focussed on grade ≥3
AEs, and biochemical markers of interest were absolute
neutrophil counts (ANC), total cholesterol (fasting)
(TC) and triglycerides (fasting) (TG), and alanine trans-
aminase (ALT). Clinical serious AEs were collected and
coded using MedDRA. Other non-serious AEs (e.g.,
headache and gastrointestinal problems) were not
included as they were not consistently collected by the
participating cohorts. All analyses were undertaken
using Stata version 12.0 (Stata Corp, College Station,
TX, USA).
RESULTS
Ninety-two children took the licensed dose of FPV.
Additionally 20 children took FPV off label, of whom
15 were aged 6–18 years and took an unlicensed dose,
and 5 were aged <6 years; these children are not
described further in this report. Of the 92 on the licensed
dose, 28 (30%) were from Belgium, 27 (29%) from
Italy, 23 (25%) from Romania, 11 (12%) from Spain,
and 3 (3%) from the UK/Ireland. The total number of
children aged 6–18 years in follow-up in these cohorts
during 2007 to 2010 was 2673, giving an overall preva-
lence of 3% taking the licensed FPV dose.
Forty-eight children (52%) were male, and of the
65 children with known ethnicity, 29 (45%) were
white, and 24 (37%) black African. Among all children,
most (71%) were infected with HIV through mother-to-
child transmission; 25% infected parenterally were all
from the Romanian cohort. A third (33%) of the total
had an AIDS diagnosis during overall follow-up.
Median age at ART initiation was 6 years
(interquartile range (IQR) 1–11 years), and median
age at start of an FPV-containing regimen was
15 years (12–17 years). Estimated median time on an
FPV-containing regimen was 52months, with a total
of 266.9 patient years of exposure overall. Half
(54%) were on an FPV-containing regimen at last
follow-up.
Biochemical toxicity data were available for 82
children. Rates of grade 3/4 events were generally
low (Figure 1). For 82 children with ANC results, 57
(70%) had normal results, 11 (13%) grade 1 results,
and 6 (7%) grade 2 results. Eight children had grade
3/4 neutropenia, with an overall rate of 5 per 100
person years (95% CI 2–9), and a higher rate in those
taking FPV for <12months (8/100 person years, 95%
CI 3–17), although this was not statistically signiﬁcant
compared with those exposed for ≥12months. Six of
the eight children were also taking lamivudine, which
is associated with neutropenia. Seven had a normal
value following the last grade 3/4 result, and all
continued FPV following the grade 3/4 event.
For 78 children with TC results, 32 (41%) had nor-
mal results and 22 (28%) grade 1 results. Two children
had grade 3 hypercholesterolemia, with an overall rate
of events of 4 per 100 person years (95% CI 2–8), and
similar rates by duration on FPV; one child subse-
quently stopped FPV because of non-compliance and
dyslipidaemia. An addition of 22 children (28%) had
a maximum of grade 2 events.
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For 77 children with TG results, 72 (94%) had normal
results and three (4%) grade 2 results. Two children had
grade 4 hypertriglyceridemia, with an overall event rate
of 3 per 100 person years (95% CI 1–6). Both continued
to take FPV following the events.
Finally, 51 children had ALT results, of whom
32 (63%) had normal results, 15 (29%) had grade 1
results, and three (6%) grade 2 results. One HBV-
co-infected child (HBsAg positive with detectable
HBV DNA and/or HBeAg positive) had one grade
3 and one grade 4 result, between 12–24months
after starting FPV (overall event rate for grade 3/4
of 2 per 100 person years (95% CI 0–6)). The child
continued on FPV, stopping due to virological failure
over a year later.
No serious AEs considered to be causally related
to FPV/r were reported. Forty-two children stopped
taking FPV during follow-up; reasons for stopping
were non-compliance/carer’s or child’s decision (n=12),
immunological/virological failure (13), gastrointestinal
tract toxicity (2), simpliﬁed treatment available (6),
resistance (1), abnormal fat redistribution (1), struc-
tured treatment interruption (1), drug unavailability
(1), ART change due to entering a trial (1), and
unknown (4).
With the use of sales data from IMS for the study
period, it is estimated that approximately 62 kg of the
oral suspension was sold in countries in this study.
The median weight of children aged 6–12 years (i.e.
likely to take the oral suspension) in this study was
40.4 kg. On the basis of a 40-kg child receiving the
recommended dose of fosamprenavir of 18mg/kg
twice daily, the estimated cumulative exposure to the
oral suspension would be 118 person years.
DISCUSSION
These ﬁndings suggest that FPV is infrequently pre-
scribed to HIV-infected children in Europe. Contextual
data from participating cohorts suggest that 3% of chil-
dren in current follow-up had taken the FPV licensed
dose, although this may be a slight underestimate of
all FPV usage as it excludes those on unlicensed doses
or children exposed during clinical trials. IMS data on
oral suspension sales similarly suggest low exposure
to FPV in children in Europe.
There are several potential reasons for the relatively
low use of FPV in Europe. Firstly, other protease
inhibitors (e.g., atazanavir) are now licensed for
children for once-daily use, and atazanavir and
darunavir are increasingly being used preferentially
in older children. Secondly, treatment guidelines vary
across Europe: recent Swedish guidelines recommend
atazanavir and darunavir over lopinavir, FPV, and
other protease inhibitors,8 whereas Italian and the
Paediatric European Network for the Treatment of
AIDS guidelines recommend FPV as a potential ﬁrst-
line PI treatment for patients aged >6 years.9,10
This study has some limitations. Firstly, AEs were
only described for periods following FPV/r initiation,
and children may have had pre-existing conditions
(e.g., neutropenia). Secondly, we could not discern
whether AEs were attributable to FPV, or to other
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Figure 1. Incidence of grade ≥3 adverse events for key laboratory markers by duration of time on FPV
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drugs in the regimen. For example, the role of ritonavir
in the development of dyslipidemia has been described,
as has zidovudine and lamivudine with neutropenia.11
In addition, exposure as calculated by IMS data were
only for oral suspension; the same size tablets are used
for children as adults; thus, it was not possible to differ-
entiate paediatric from adult sales volumes. Our esti-
mates were based on the assumption that all paediatric
use was in children weighing 40 kg.
However, the number and rate of grade ≥3 events
were low, with no discernible trend by duration of
exposure. There were an elevated number of grade 2
hypercholesterolemia events, and increased serum
cholesterol has previously been described in patients
treated with protease inhibitors.12 No serious clinical
AEs related to FPV/r were reported.
In summary, our results suggest that long-term
licensed dose FPV-containing regimens appear to be
generally well tolerated with few reported toxicities
in HIV-infected children in Europe, although relatively
infrequently prescribed. Any toxicities reported were
consistent with the known safety proﬁle of FPV. No
serious events were reported.
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KEY POINTS
• Fosamprenavir, along with low-dose ritonavir, is
infrequently prescribed to children with HIV in
Europe.
• Findings suggest that the long-term licensed dose
is well tolerated, and few toxicities were reported.
• No serious events associated with fosamprenavir
were reported.
• Prospective cohort studies that routinely collect
long-term safety data can provide a robust source
of information for pharmacovigilance.
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